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ABSTRACT 
It is generally recognised that only relatively small molecular weight (typically < ~500 Da) 
drugs can effectively permeate through intact stratum corneum.   Here, we challenge this 
orthodoxy using a 62-nucleotide (MW=20,395) RNA-based aptamer, highly specific to the 
human IL-23 cytokine, with picomolar activity.  Results demonstrate penetration of the 
aptamer into freshly excised human skin using two different fluorescent labels.  A dual 
hybridisation assay quantified aptamer from the epidermis and dermis giving levels far 
exceeding the cellular IC50 values (> 100,000-fold) and aptamer integrity was confirmed 
using an oligonucleotide precipitation assay.  A Th17 response was stimulated in freshly 
excised human skin resulting in significantly upregulated IL-17f, and 22; topical application 
of the IL-23 aptamer decreased both IL-17f and IL-22 by approximately 45% but did not 
result in significant changes to IL-23 mRNA levels, confirming that the aptamer did not 
globally suppress mRNA levels.  This study demonstrates that very large molecular weight 
RNA aptamers can permeate across the intact human skin barrier to therapeutically relevant 
levels into both the epidermis and dermis and that the skin penetrating aptamer retains its 
biologically active conformational structure capable of binding to endogenous IL-23. 
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INTRODUCTION  
It is widely accepted that the intact stratum corneum (SC) provides the primary barrier to 
topical and transdermal drug delivery and so restricts the therapeutic targets that can be 
accessed topically.  Relatively few molecules have the appropriate physicochemical and 
therapeutic properties to allow topical and transdermal administration.  It is generally 
recognised that only relatively small molecular weight (typically <500 Da) and moderately 
lipophilic (log P(oct/water) 1-3.5) drugs can effectively permeate through the SC (Bos and 
Meinardi, 2000; Williams, 2003). 
 
The introduction of biological therapeutic agents has revolutionised the treatment of 
psoriasis, a chronic inflammatory skin disorder.  Although effective when delivered 
systemically, the large size of proteins, including monoclonal antibodies, domain antibodies, 
and even Fab fragments, is thought to preclude their development as topical medicines.  
Aptamers are oligonucleotide-based molecules that can specifically bind to proteins or other 
cellular targets; aptamers have been approved for macular degeneration, and others are in 
clinical development for cancer, haemophilia, anaemia, and diabetes (Darisipudi et al, 2011; 
Ng et al, 2006; Parunov et al, 2011; Schwoebel et al, 2013).  Aptamers offer a significant 
advantage over antisense molecules because their structure and composition can be modified 
while retaining pharmacological activity and they possess conformational plasticity and 
flexibility (Nomura et al, 2010).  Systematic evolution of ligands by exponential enrichment 
(SELEX) has accelerated the discovery and development of aptamers allowing functional 
isolation of oligonucleotides against specific targets that could be used to treat skin diseases 
(Keefe et al, 2010). 
 
Psoriasis is driven by activated T cells (Di Cesare et al, 2009).  Elevated levels of IL-23 and 
Th17-related cytokines in lesional skin biopsies encouraged targeting of the IL-23/Th17 
pathway for psoriasis treatment (Blauvelt, 2008).  Ustekinumab, a human IgG1κ monoclonal 
antibody (mAb) that binds to the p40 protein subunit of IL-12 and IL-23 cytokines, is 
approved for moderate/severe plaque psoriasis.  However, there are risks associated with long 
term systemic p40 inhibition given the role of IL-12 in intracellular microbial response and 
tumour suppression (Koutruba et al, 2010; Tausend et al, 2014).  To circumvent this, a human 
mAb specifically directed against IL-23 gave positive clinical responses in patients with 
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moderate-to-severe psoriasis, suggesting that neutralizing IL-23 alone is a promising 
psoriasis therapy (Sofen et al, 2014). 
 
We have developed and optimized an aptamer inhibitor of IL-23 for topical treatment of 
psoriasis (Figure 1).  This water-soluble 62-nucleotide (MW=20,395) aptamer has high 
affinity and specificity to human IL-23 cytokine.  Employing a well-validated model, it has 
been shown that, without physically disrupting the SC, this large molecular weight RNA 
based aptamer can penetrate into and permeate through human skin.  Analyses to extract, 
detect and quantify the macromolecule in human skin showed the IL-23 aptamer was present 
at therapeutically relevant levels.  Finally, delivery was confirmed through a cytokine 
induced inflammatory ex vivo human skin model (Smith, et al, 2016).  This study shows the 
passive delivery of a large molecular weight aptamer across intact human skin.   
 
RESULTS 
The IL-23 aptamer is biologically active 
Biological activity of the aptamer was confirmed in three different assays.  Inhibition of IL-
23 dependent stimulation of STAT3 activity in PHA-Blast cells showed that the 61-mer 
minimer (IC50 0.075 nM ± 0.030 nM) was more potent than the parent full length (84-mer) 
IL-23 aptamer (IC50 0.26 nM ± 0.036 nM); the activity of both aptamers was greater than the 
control anti-p19 antibody (IC50 0.69 nM ± 0.12 nM).  Secondly, the aptamer blocked 
endogenous IL-23 activation in PHA/IL-2 activated T-cells, evaluated by measuring levels of 
phospho-STAT3.  Finally, the IL-23 aptamer did not inhibit IL-12 activation of PHA/IL-2 
activated T-cells; many IL-23 antagonists also inhibit IL-12 since they share the p40 subunit 
but our IL-23 aptamer only inhibits IL-23 activation and not IL-12 activation, similar to the 
anti-p19 antibody.  Experimental methods and representative inhibition curves can be found 
in Supplementary Information (S1). 
 
The IL-23 aptamer penetrates human skin 
Passive penetration of topically applied IL-23 (20.4 kDa) aptamer through human skin was 
assessed using freshly excised skin with and without a fully functional stratum corneum 
barrier (Figure 2a).  Fluorescently labelled IL-23 aptamer (21.4 kDa) was formulated in an 
oil-in-water cream vehicle previously described to aid delivery of macromolecules (Mehta et 
al, 2000).  A finite dose (10 mg/cm2 of formulation containing 1% aptamer) was applied to 
skin mounted in flow-through diffusion cells.  To ensure the washing procedure effectively 
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removed residual aptamer from the skin surface and to assess tissue auto fluorescence, the 
medicated cream was applied and immediately removed (zero hour sample).  No fluorescence 
in intact or partially compromised skin confirmed the washing procedure effectively removed 
residual aptamer from the skin surface.  Interestingly, skin with the SC removed allowed 
permeation at this zero hour sample suggesting the aptamer permeates through the viable 
epidermis almost immediately and is not further limited by tight junctions in the epidermis.  
In contrast, a single domain antibody (dAb) fragment (13.1 kDa) failed to permeate into the 
viable epidermis of tape stripped skin (Figure 2b) demonstrating that these junctions can 
regulate passive diffusion of large molecular weight biological agents.  After four hours of 
topical exposure, the IL-23 aptamer penetrated not only fully and partially compromised 
tissue, but also through intact human skin, with an intensity gradient decreasing from the skin 
surface to the basement membrane.  Interestingly, after dosing full thickness intact skin, no 
aptamer was detected in the receiver solution but rather the macromolecule appears to be 
retained in the tissue, perhaps via cellular uptake (see below). 
 
To confirm that the aptamer indeed penetrated the skin and that fluorescence was not simply 
due to dissociation of the label, the IL-23 aptamer was extracted from non-compromised 
(Unt) and partially compromised (Abr) skin samples, visualized fluorescently on a 
polyacrylamide gel and compared to the IL-23 aptamer dylight 488 standard (IL-23 aptamer) 
and a 28-mer SDF-1 aptamer (28-mer) (Figure 2c).  Concordance of skin extracted aptamer 
with the IL-23 aptamer dylight 488 standard shows delivery of intact labelled 
macromolecules to these skin layers, providing evidence that the fluorescence images are not 
from dissociation of the label though this cannot be fully discounted from the images in (a) 
and (b) alone.   
 
Delivery into intact human abdominal skin with longer exposures using a second fluorescent 
label (Cy3) was also performed in order to evaluate cellular uptake, but with dosing of the IL-
23 aptamer from an aqueous vehicle.  Again the wash procedure removed aptamer from the 
skin surface (zero hour samples), confirming that fluorescence in the tissue results from 
topical penetration through the intact barrier (Figure 3).  The IL-23 aptamer penetrated intact 
skin within 6 hours with fluorescence intensity increasing up to 24 hours.  Fluorescence was 
detected in the extracellular matrix, as seen by the fluorescent gradient through the viable 
epidermis, and intracellular, confirmed by confocal imaging with fluorescence (potentially 
within the nucleus) of keratinocytes in the ex vivo skin sections.  This accords with anti IL-
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17A RNA aptamer uptake by cultured cells (Doble et al, 2014).  Importantly, the distribution 
of the IL-23 aptamer suggests that topically delivered aptamers could modulate both 
intracellular and extracellular targets in the skin. 
 
Detection and Quantitation of IL-23 aptamer in human skin   
The fluorescence images suggest topical delivery of RNA aptamers through intact SC.  As 
the current paradigm is that biomacromolecules cannot penetrate intact human skin, a dual 
hybridization assay (DHA) was developed where detection and capture probes quantified IL-
23 aptamer extracted from the skin.  The DHA selectivity and sensitivity was systematically 
verified through removal of nucleotides from both 5’ and 3’ ends of the aptamer and the 
capture/detection probes; single nucleotide removals resulted in loss of detection.  Complete 
loss was observed when two or more nucleotides were removed at the expected skin 
concentration of <1,000 pM.  The IL-23 aptamer was formulated into both cream and 
microemulsions, suggested as optimal vehicles for topical delivery of peptides and proteins 
(Russell-Jones and Himes, 2011), applied to freshly excised human skin mounted in flow 
through diffusion cells and removed at 0, 6 and 24 hours.  The epidermis was removed by 
heat-separation (the temperature of which has been previously shown not to damage the 
aptamer) to allow extraction and quantification of the IL-23 aptamer in both the epidermis 
and dermis.  Very low concentrations of IL-23 aptamer (0.09 – 0.36 µg) were in the 
epidermis and dermis after the initial (control) washing procedure (Figure 4a) but these levels 
were subtracted from the six and twenty four hour treated samples to account for any aptamer 
remaining after the wash procedure (Figure 4b). 
 
Both vehicles delivered IL-23 aptamer to concentrations that exceeded by several orders of 
magnitude the desired cellular IC50 into both the epidermis and dermis, with delivery 
increasing in a time dependent fashion (Figure 4b).  Interestingly, the cream delivered more 
aptamer compared to the microemulsion; 3.4 and 5.5 fold greater levels in the epidermis and 
dermis respectively following 6 hours of application (P<0.009 epidermis and P<0.06 dermis) 
with 1.5 (epidermis) and 2.3 fold (dermis) increases after 24 hours treatment  (P<0.06 
epidermis and P<0.04 dermis).  The cream delivered 4 µg (14 µM, 4% of the applied aptamer 
dose) and 12 µg (37 µM, 12% of the applied dose) of IL-23 aptamer into the epidermis after 
6 and 24 hour treatment respectively, which is approximately 43,000 and 119,000-fold above 
the cellular IC50 as shown in STAT3 activation of primary human T-cells (Figure 1e).  The 
cream delivered 0.6 µg (0.9 µM, 0.6% of the applied aptamer) and 0.7 µg (1.2 µM, 0.7% of 
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the applied dose) to the dermis after 6 or 24 hours respectively, i.e. some 2,500 and 3,400 
fold above the cellular IC50 for the IL-23 aptamer.  In parallel, aptamer was also applied from 
an aqueous (control) solution at 10 mg/cm2 but provided lower delivery; for example, 6 h 
post dose, 0.3 and 0.1 µg of the aptamer was detected in the epidermis and dermis 
respectively. 
 
To demonstrate that the aptamer did not degrade during transit through the skin, an 
oligonucleotide precipitation assay using the DHA capture probes extracted the IL-23 
aptamer from skin and was then visualized by polyacrylamide gel electrophoresis.  The 
extracted RNA bands aligned with the IL-23 aptamer standards.  Further, the relative band 
intensities correlated with the quantified values from the above DHA.  Similar to the relative 
aptamer levels delivered by the two vehicles in the DHA, a more intense band was visualized 
for the cream compared to the microemulsion (Figure 4c and d). 
 
Topical application of IL-23 aptamer inhibits Th17 derived cytokines in human skin 
The above studies demonstrate that therapeutically relevant levels of aptamer can be 
delivered to, and recovered from, intact human epidermal and dermal tissue.  An ex vivo 
human Th17 polarized skin model was used to further confirm delivery and intrinsic 
pharmacodynamics of this aptamer.  Freshly excised human skin was mounted in static cells 
with growth media as the reservoir, and the skin was stimulated to induce a Th17 response 
(Smith, et al, 2016).  The activity of the topically delivered IL-23 aptamer in the skin was 
compared to a basolateral treatment with IL-23 aptamer and an ROR gamma inverse agonist.  
The Th17 stimulating conditions significantly upregulated IL-17f, and 22 (Figure 5).  Topical 
application of the IL-23 aptamer (1% aqueous solution of IL-23) decreased both IL-17f and 
IL-22 by approximately 45% (p<0.001 and 0.05 respectively) similar to those observed when 
IL-23 aptamer was included in the media (10M IL-23).  The addition of IL-23 aptamer, 
either topically or basolaterally, did not result in significant changes to IL-23 mRNA levels, 
confirming that the aptamer was not globally suppressing mRNA levels, but was specific for 
IL-17f and IL-22.  Interestingly, the reduction of IL-22 mRNA following topical application 
of IL-23 aptamer was similar to that of the small molecule ROR gamma inverse agonist.  
These results confirm that skin penetrating aptamer retains the biologically active 
conformational structure capable of binding to endogenous IL-23.   
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DISCUSSION 
In general, the literature does not support the ability of large molecules, particularly 
biomacromolecules, to significantly transit the stratum corneum passively to gain entry into 
the skin.  Here, it is demonstrated that a 62-nucleotide (MW=20,395) mRfY aptamer not only 
transits the SC, but does so to therapeutically relevant levels in the epidermis and dermis.  
Multiple approaches demonstrate passage through the intact SC into the viable epidermis, 
including (i) fluorescently labelled aptamer (using two different labels) confirmed with gel 
electrophoresis, (ii) confocal microscopy, and (iii) dual hybridization assay using capture and 
detection probes with oligonucleotide precipitation.  In contrast, topically administered 
domain antibodies failed to penetrate the SC or enter the viable epidermis.  The aptamer 
within skin far exceeded the desired cellular IC50 values (119,000-fold > IC50 in the 
epidermis; 3,400-fold > IC50 in the dermis) following 24 h delivery from a simple cream 
formulation.  Additionally, intracellular and extracellular localization was observed.  
Nonspecific uptake of an RNA aptamer into primary human keratinocytes has been 
previously reported (Doble et al, 2014), though the authors noted that site-specific (i.e., 
topical) treatment to reduce inflammatory mediators produced by deeper keratinocytes would 
be problematic due to aptamer uptake by upper skin layer keratinocytes.  In our studies, 
topically delivered IL23 aptamer suppressed IL-17 and IL-22 mRNA production in a 
cytokine stimulated ex vivo human skin model, showing that the aptamer is available to exert 
a therapeutic effect in deeper skin layers confirming the fluorescence, dual hybridization 
assay, and oligonucleotide precipitation assay data.     
 
There are conflicting reports on the feasibility of topical delivery of antisense 
oligonucleotides, though notably none are clinically approved (Butler et al, 1997; Mehta et al, 
2000; White et al, 1999; White et al, 2002).  Aptamers are a class of oligonucleotide-based 
technologies that can bind to a wide range of molecules and have been mainly used for 
diagnostics and systemic therapeutics.  In contrast to antisense oligonucleotides, aptamers 
offer significant conformational plasticity and flexibility (Nomura et al, 2010).  The structure 
and composition of aptamers can be modified but retain significant activity, whereas 
modifications to antisense molecules are avoided because of their potential impact on 
efficacy.  The literature reports rapid systemic clearance of aptamers, limiting unwanted side 
effects and restricting the biologic effects of topically administered aptamers to the skin 
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(Healy et al, 2004; Watson et al, 2000).  Thus, RNA aptamers represent a broad class of 
biological compounds that could be used for local targeting of skin diseases. 
 
Since our results contradict the “normal” rules governing molecular properties and topical 
drug delivery, numerous potential mechanisms by which the aptamer enters the tissue were 
explored (and will be described in detail in a further publication).  However, the role of water 
was probed by hydrating the stratum corneum for 12 h prior to dosing and by occluding (or 
not) the both pre-hydrated and none pre-hydrated tissue, using finite (5-10 mg/cm2) and 
infinite (300 mg/cm2) doses of the aptamer in an aqueous vehicle alongside blank controls for 
detection at 6 and 15 h in the epidermis and dermis, as above.  In short, the water gradient 
across skin was removed by fully hydrating or occluding the stratum corneum; pre-hydrating 
the tissue was broadly detrimental but occlusion was generally beneficial, most notably for 
infinite dosing of none pre-hydrated skin.   Delivery of this highly water soluble aptamer thus 
appears to be influenced by changing the water gradients across the skin. 
 
Since the conformational structure of aptamers can be disrupted by metal ions (notably Ca2+ 
and Mg2+) that are present in human skin, aptamer delivery from aqueous vehicles was 
compared to delivery when the vehicle included 100 or 10 mM EDTA, or when 10 mM 
CaCl2 or 10 mM MgCl2 was added; similar studies also used these adjuncts in the receiving 
fluid.  Neither chelating the ions with EDTA nor adding additional ions significantly 
impacted aptamer amounts in either the dermis or epidermis at 6 or 15 h post dosing. 
 
Though active transport mechanisms are widely regarded as absent in the stratum corneum, it 
is feasible that some carrier systems may operate in the deeper skin layers.   This was 
explored by comparing aptamer delivery at 4 and 32C; amounts in the dermis and epidermis 
at 6 and 15 h post dosing were invariant with temperature confirming passive rather than 
active transport. 
 
The optimised IL-23 aptamer is folded and the role of the secondary structure in its skin 
penetration was explored through comparison with a series of four variants containing 
secondary or tertiary modifications. 24 hour post dosing, all variants were detected in the 
epidermis; approximately 10% of the applied dose of the optimised aptamer was detected 
whereas 17 – 5% of the variants doses were detected in this layer.  Different IL-23 aptamers 
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with a range of molecular weights (from an 85-mer, mw = 28,950 Da to a 39-mer, mw = 
13,435) were applied alongside a second series of aptamers against the transferrin receptor 
(85-mer, mw = 29,348; 45-mer, mw = 15,512; 36-mer, mw = 12,486).  Fluorescence imaging 
showed that all the RNA-based aptamers penetrated into intact human skin and were 
visualised within the epidermis.  In contrast to small “conventional” drugs, no molecular 
weight dependence on uptake was seen for the aptamers and, as a class, they appear to be 
able to penetrate the stratum corneum. 
 
In summary, numerous mechanisms for aptamer uptake into intact human have been 
explored.  From the fluorescence images, there is no evidence to suggest that delivery is 
principally via the shunt routes.  For the large RNA-based structures, uptake is independent 
of molecular weight (between 12.5 and 29.3 kDA) and was unaffected by our secondary and 
tertiary conformational modifications. There is no evidence for active transport and divalent 
cation effects were not detected.  Some delivery-dependence on tissue water content is seen, 
perhaps not surprisingly considering that these molecules are highly water soluble, but pre-
hydrating the skin was detrimental whereas occlusion was generally beneficial.     
              
This study demonstrates that, despite being very large molecular weight biotherapeutic 
agents, RNA aptamers can permeate across the intact human skin barrier to therapeutically 
relevant levels in both the epidermis and dermis. 
 
MATERIALS AND METHODS 
 
IL-23 Aptamer 
Following in vitro selection (Supplementary Information S2), the IL-23 aptamer was fully 
minimized and optimised from 84 to 61 nucleotides using computational folding prediction 
programs and systematic deletion. Modifications at the 2’ position of the sugar for each base 
were evaluated to improve activity as well as predicted in vitro stability either by substitution 
of a 2’Fluoro with a 2′-O-methoxyethyl(2'OME) (2’F -> 2’OMe) or substitution of a 2′-O-
methoxyethyl with a 2’Fluoro (2’OMe->2’F).  All tolerated or potency increasing 
substitutions were combined with all tolerated deletions within the oligonucleotide.  
Appendage of a 3’-inverted thymidine residue, to increase nuclease resistance, resulted in a 
62 nucleotide long molecule (IL-23 aptamer) composed of ten 2'-O-methyladenosines (mA), 
one 2'-fluoroadenosine (fA), fourteen 2'-Omethylguanosines (mG), six 2'-fluoroguanosines 
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(fG), three 2'-O-methylcytosines (mC), thirteen 2'-fluorocytosines (fC), one 2'-O-
methyluridine (mU), thirteen 2'-fluorouridines (fU) and the 3’-terminus is capped with a 
single inverted deoxythymidine residue to protect against nuclease degradation (MW= 
20,395).  The IL-23 RNA mRfY aptamer was conjugated with dylight 488 or Cy3 fluorescent 
labels as an amide conjugate during chemical synthesis. 
   
Preparation of Human Ex Vivo Skin 
Full-thickness human skin was obtained within several hours from patients undergoing 
elective abdominoplasty.  The acquisition, written informed consent form (IFC), and protocol 
for use were approved by an independent Investigational Review Board (Pearl IRB, 
Indianapolis, IN).   Immediately after collection, the skin was transferred to phosphate 
buffered saline (PBS) and kept at 4°C during transit.  Subcutaneous fat was removed from the 
samples and the skin rinsed briefly in Hank’s balanced salt solution with 1% 
antibiotic/antimycotic.  Split-thickness dermatomed skin was prepared by placing full 
thickness skin on high-density foam blocks and cut to specified thickness (250 ± 100 µm, 500 
± 100 µm, or  750 ± 100 µm) using an Electro-Dermatome.   
 
Skin was left untreated for uncompromised barrier (intact), pre-treated with sodium 
bicarbonate crystals to partially disrupt the barrier (abraded), or pre-treated with 
approximately 28 tape strips to completely remove the barrier (tape stripped).  To confirm SC 
disruption, skin sections immediately after treatments were fixed in formalin and paraffin-
embedded, sectioned and stained with H&E.   
 
In Vitro Skin Penetration 
Two different flow-through diffusion cells (PermeGear, Inc and Eclectech, Inc.) or static 
diffusion cells (PermeGear, Inc) were used to assess aptamer permeation and activity. 
 
Flow through diffusion system:  Flow-through diffusion cells were placed in cell warming 
supports to maintain the skin surface temperature at 32 ± 2°C.  Cells were connected to multi-
channel peristaltic pumps via Tygon® tubing, and the cell outlets were fitted with poly ether 
ether ketone (PEEK) tubing, angled to drip into 96-well plates or 20 mL vials on fraction 
collectors.  Dermatomed ex vivo human skin was mounted in the diffusion cells, SC side up.  
Donor compartment blocks placed on the skin were secured to provide a leak proof seal, 
exposing a surface area of 1.0 cm2.  The pumps were adjusted to maintain sink conditions 
with a flow-rate of 0.300 mL/hour (5.0 µL/minute) or 3.6 mL/hour (60 µL/minute) for the 
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ChanneL cells and PermeGear Cells respectively with phosphate buffered saline used as the 
receiving fluid.  Both systems were allowed to equilibrate for ~30 min prior to dosing. 
 
Static diffusion cell system:  Static (Franz-type) cells were used for the Th17 stimulated 
human ex-vivo skin model.  Briefly, dermatomed ex vivo skin was mounted SC side up on 
static diffusion cells with an average surface area of approximately 0.6 cm² and a receiver 
compartment volume of approximately 2.0 mL.    The receiver chamber was initially filled 
with cornification media and incubated at 37°C.   Then skin was dosed topically or 
systemically (in the media) with aptamer for twenty-four hours before the receiver solution 
was replaced with Th17 stimulation cocktail. Twenty-four hours after stimulation, the tissue 
was harvested, minced before RNA isolation and quantitation.  Full details can be found in 
Supplementary Information S4. 
 
Dosing and vehicles:  The IL-23 aptamer was formulated at 1% in either an oil-in-water 
cream (62.5% Di water, 0.5% Benecel MP333C, 10% Isopropyl Myristate, 10% Glyceryl 
Monostearate NSE 400, 15% Polyoxyl-40-stearate, and 1% Phenonip), microemulsion (5% 
Isopropanol, 20% Di water, 1.5% benzyl alcohol, 30% Drakeol-5, 15% Brij 02, 15% Brij 
010, 12.5% cetrimonium chloride) or water vehicle (controls; 98.9% DI Water, 0.1% 
Polysorbate 20, 1% Benzoyl alcohol).  The formulations were uniformly dosed onto the SC 
surface using a positive displacement pipette, set to deliver 10 mg/cm2.  The donor chambers 
were left open to ambient conditions, i.e., the skin was not occluded. 
 
Post-dosing skin washing and isolation:  At predetermined time points (0, 4, 6, 15, or 24 
hours), the skin was thoroughly cleansed.  Three cotton buds; dry, wet (1:9 Hexane:MeOH or 
0.05% Tween 20 in PBS) and dry were used to remove the surface formulation and was 
immediately followed by 3 consecutive tape strips (Scotch® Transparent Tape 175L-WG).  
These samples were not analysed and considered as surface deposited compound, i.e. not 
penetrating the skin.  Heat separation of skin layers by soaking in hot water was avoided to 
prevent migration of aptamer or biomarkers.  Thus, post treatment, the skin was placed in an 
oven at 60°C for 2 minutes, and the epidermis was carefully separated from the dermis using 
forceps.  Epidermis and dermis samples analysed by the dual hybridization assay (DHA) 
were placed into separate vials and 1 mL of 0.25 % trypsin was added to each.  Vials were 
placed in an oven set at 37°C for 16 to 20 hours and then the extraction diluent was removed 
and centrifuged at 13,000 RPM for 10 minutes to remove residual materials. 
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Conjugated Fluorescence Detection 
Dried skin (cleaned as above) was placed epidermis side down on a clean cutting board and 
smaller sections cut with a clean razor blade to avoid carry over.  Sections were placed on 
edge in 15x15 mm moulds and immediately frozen in OCT using an isopentane/dry ice bath.  
Moulds were then wrapped in aluminium foil, and stored at -80°C.  For immunofluorescence 
(IFC), the frozen blocks were placed into a -20°C cryostat 3 minutes prior to sectioning.  Five 
µm sections were cut and mounted on individual Richard Allen Bond-Rite slides which were 
fixed in -20˚C acetone for 10 minutes and then air dried for 30 minutes.  Slides were rinsed 
three times with Tris Buffered Saline (TBS) (Dako).  Slides with nuclear staining were cover-
slipped with ProLong® Gold Antifade Reagent with diamidino-2-phenylindole (DAPI) 
(Invitrogen).  Permeation was assessed using a fluorescence microscope fitted with 
appropriate filters for the fluorophore.  Images were taken using a Leica DMRXA2 
microscope mounted with a Nikon DS-QiMc monochromatic camera and NIS Elements BR 
3.2 software.  For each independent experiment, skin was also dosed with vehicle alone 
(control) and all pictures were taken using the same exposure time to discard auto-
fluorescence signals from skin or fluorescence from residual vehicles. 
 
Dual Hybridization Assay 
The dual hybridization assay (DHA) has been previously used with plasma and vitreous 
humour samples (Drolet et al, 2000).  This assay is analogous to an ELISA where aptamer is 
allowed to hybridize to capture and detection DNA oligonucleotide probes.  The capture 
probe (ARC35141; Integrated DNA Technologies) binds to the 13 nucleotides at the 5'-
terminus of the aptamer and was covalently attached to magnetic beads via a 3'-terminal 
amino linker.  The detection probe (ARC35156; Integrated DNA Technologies) was 
complementary to the 15 nucleotides at the 3'-terminus of the aptamer and was biotinylated at 
the 5'-terminus.  Further details are available in the accompanying Supplementary 
Information (S3) 
 
The recovered aptamer (mass per cm2) from each skin layer was converted to concentration 
(µmol/L) where the volume of epidermis was assumed to be 0.015 cm3 and the volume of 
dermis was assumed to be 0.035 cm3.    
 
 
Oligo-Protein Precipitation Assay 
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To confirm aptamer quantitation by DHA, an assay was developed, termed oligo-
precipitation “OP”.  This used the same biotinylated capture primers from the DHA to mix 
with the 100 µL of digested skin samples (epidermis or dermis).  Samples were heated and 
cooled to allow primer to hybridize.  Streptavidin beads were added to pull down the 
aptamer-primer complex.  The aptamer was then eluted off the beads, loaded onto a 15% urea 
gel and stained with Sybr Gold to visualize and compare aptamer bands. 
 
Th17 Stimulated Human Ex Vivo Skin Model 
Th17-skewed cytokine expression was induced from ex vivo skin-resident immune cells 
according to our earlier report demonstrating efficacy of a RORγ inverse agonist small 
molecule (Smith et al, 2016).  Details can be found in Supplementary Information (S4).  
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FIGURE LEGENDS 
Figure 1.  Predicted secondary structure of the fully minimised and optimized IL-23 
aptamer using mfold.   
Figure 2.  Penetration of IL-23 aptamer through compromised and uncompromised 
human skin.  (a).  Penetration of IL-23 dylight 488 labelled aptamer (green) into intact, 
abraded and tape stripped human abdominal skin showing aptamer distribution after washing 
from the skin surface immediately after dosing (wash control) and 4 hours post dosing. (b) 
Distribution of a single domain fully human antibody (dAb) fragment (13.1 kDa) dosed 
topically onto tape stripped skin. (c) Polyacrylamide gel of fluorescent aptamer extracted 
from intact (untreated, UNT) and abraded (Abr) skin compared to IL-23 aptamer dylight 488 
standard (IL-23 Aptamer) and a 28-mer SDF-1 aptamer (28-mer).  Scale bar = 50µm.  
Figure 3.  Topically applied IL-23 aptamer penetrates human skin and into 
keratinocytes.  (a) Penetration of IL-23 Cy3 labelled aptamer (orange) into intact human 
abdominal skin after zero (wash control), 6 and 24 hours post dosing.   (b). Uptake of IL-23 
aptamer into skin keratinocytes (dashed lines indicating the epidermal junction). (c)   
Intracellular uptake of aptamer (green) with nuclear DAPI stain (blue) used for cellular 
orientation.  Scale bar = 100µm. 
Figure 4.  Dual Hybridization Assay (DHA) and Oligonucleotide Precipitation to 
quantify intact aptamer within skin.   (a) Aptamer recovery by DHA from epidermis 
following zero (wash control), 6 and 24 hours application from a microemulsion and cream 
formulation. (b)  Aptamer recovery by DHA from dermis following zero (wash control), 6 
and 24 hours application from a microemulsion and cream formulation. (c) Polyacrylamide 
gel of aptamer extracted from the epidermis by oligonucleotide precipitation following 
dosing from a cream (Crm) compared to the IL-23 aptamer standard (Std=80 ng). (d) 
Polyacrylamide gel of aptamer extracted from the dermis by oligonucleotide precipitation 
following dosing from a cream (Crm) and microemulsion (ME) compared to IL-23 aptamer 
standards (40ng, 20ng, 10ng, 5ng, 2.5ng, 1.25ng, 0.6ng). DHA data shown as mean ± SEM, 
n=5. 
Figure 5.  Topical application of IL-23 aptamer inhibits Th17 derived cytokines in 
human skin.  Freshly excised human abdominal skin was mounted and clamped in place 
using static cells containing growth media and stimulated twenty four hours later to induce a 
Th17 response.  The skin was treated topically twice with 8 µL of IL-23 aptamer (210 
µg/cm2) in an aqueous vehicle before and concurrent with Th17 stimulation.  IL-23 aptamer 
(10 µM) and a RORgamma inverse agonist (10 µM; small molecule) was included in the 
media as systemic controls.   Twenty-four hours post stimulation, skin was harvested and 
relative transcript levels of Th17-type cytokines, IL-17f (a), IL-22 (b), and IL-23 (c) were 
determined by qPCR.  Bars represent the mean percent of maximum stimulation (set to 
100%) from 3 different skin donors (n=3).   
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Figure 1.  Predicted secondary structure of the fully minimised and optimized IL-23 
aptamer using mfold  
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Figure 2.  Topical application of IL-23 aptamer penetrates compromised and 
uncompromised human skin.   
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Figure 3.  Topical application of IL-23 aptamer penetrates human skin and into 
keratinocytes.   
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Figure 4.  Dual Hybridization Assay demonstrates that topical application of IL-23 
aptamer penetrates human skin at therapeutic levels.   
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Figure 5.  Topical application of IL-23 aptamer inhibits Th17 derived cytokines in 
human skin.   
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Supplementary Information.  S1 
The IL-23 aptamer is biologically active 
STAT3 Activity in PHA-Blast cells 
Endogenous IL-23 was prepared from the conditioned media of activated purified primary 
human monocytes by affinity purification.  Peripheral Blood Mononuclear Cells (PBMC) 
were obtained from buffy coats prepared from fresh human blood.  Monocytes were isolated 
by adherence to CD14 coated magnetic beads (Miltenyi, Cologne, Germany).  To induce and 
enhance IL-23 expression, monocytes were treated with LPS and anti-IL-10 blocking 
antibodies.  After 24 hours, conditioned media was collected and frozen.  Sepharose NHS 
agarose beads (Sigma, St. Louis, MI) were coupled with non-neutralizing p19 monoclonal 
antibodies (eBioscience, San Diego, CA) and incubated overnight with pooled conditioned 
media from multiple donors.  Beads were washed and endogenous IL-23 eluted with acid, 
and neutralized with a TRIS-base, BSA containing buffer.  The eluate was dialyzed with 
PBS, and the purified protein was aliquoted and frozen.  Expression of IL-23 from monocytes 
was confirmed by testing conditioned media using the p19/p40 enzyme-linked 
immunosorbent assay (ELISA) from eBioscience (San Diego, CA).  The ELISA plate was 
coated with an anti-p19 antibody and captured antigen was detected with an anti-p40 
antibody, thus specifically measuring the IL-23 cytokine.  A titration of purified protein was 
applied to IL-2/PHA activated T-cells for 15 minutes to induce the phosphorylation of 
STAT3.  pSTAT3 (phospho-STAT3) in cell lysates were subsequently measured by ELISA 
(Cell Signalling Technologies, Danvers, MA).  Phosphorylated STAT3 from PHA Blast cells 
treated with purified endogenous IL-23 was measured by colorimetric ELISA after 15 
minutes of stimulation with dialyzed eluate.  The endogenous protein was subsequently used 
in PHA Blast phospho-STAT3 assays at a volume falling in the linear range of the curve.  
Titration curves were generated using PHA blasts from seven different donors and tested at 
concentrations between 0.00057 and 500 nM. Seven 12-point titration curves, each in 
duplicate, were used to calculate a mean (+/- SEM). 
Phospho-STAT3 assay 
IL-23 aptamer inhibition of endogenous IL-23 activation of PHA/IL-2 activated T- cells was 
tested by measuring levels of phospho-STAT3.  Binding of IL-23 to its receptor on activated 
T-cells stimulates several STAT pathways, including STAT3.  PBMC’s from fresh human 
blood (Archemix) were isolated by centrifugation in a histopaque gradient and treated with 
PHA/IL-2 to enrich for T-cells and to upregulate IL-23 receptors.  Cells were serum starved 
and treated with endogenous IL-23 for 15 minutes, then lysed.  Relative levels of phospho-
STAT3 in IL-23 treated lysates, in the presence and absence of IL-23 aptamer or a 
neutralizing p19 antibody, were measured by ELISA (Cell Signalling Technologies, Danvers, 
MA).  Titrations of aptamer/antibody were used to generate inhibition curves from which the 
cellular IC50 determinations were made. 
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Results 
Three different cellular assays demonstrated biological activity of the aptamer. (I) Inhibition 
of IL-23 dependent stimulation of STAT3 activity in PHA-Blast cells showed that both the 
parent full length IL-23 aptamer (84-mer) and minimer (61-mer) were biologically active 
(Figure 1a).  The parent cellular IC50 was 0.26 nM ± 0.036 nM and the more potent 
minimized aptamer IC50 was 0.075 nM ± 0.030 nM (Figure 1b).  The activity of both 
aptamers was greater than the control anti-p19 antibody, cellular IC50=0.69 nM ± 0.12 nM.  
(II) Receptor binding of IL-23 on activated T-cells stimulates several STAT pathways, 
including STAT3. The ability to block endogenous IL-23 activation in PHA/IL-2 activated T-
cells, evaluated by measuring levels of phospho-STAT3, also demonstrated aptamer 
biological activity; representative anti-p40 antibody and IL-23 aptamer inhibition curves are 
in Figure 1b.  (III) Finally, the ability of the IL-23 aptamer to inhibit IL-12 activation of 
PHA/IL-2 activated T-cells was evaluated.  Similar to IL-23, IL-12 receptor binding on 
activated T-cells stimulates several STAT pathways, including STAT3 and many IL-23 
antagonists also inhibit IL-12 since they share the p40 subunit. The IL-23 aptamer only 
inhibits IL-23 activation and not IL-12 activation, much like the anti-p19 antibody.  
Representative p19 antibody and IL-23 aptamer inhibition curves (Figure 1c) show that the 
IL-23 aptamer is specific for IL-23.  From seven 12-point titration curves, each in duplicate, 
the mean (±SEM) cellular IC50 was 296 ± 90 pM for the IL-23 aptamer (Figure 1d).  The IL-
23 aptamer has > 500 nM binding affinity to IL-12 as assessed by a radiolabelled dot blot 
assay.    
 
 
IC50 (nM) 
Donor p19 IL-23 Aptamer 
1 2.84 0.714 
2 8.82 0.075 
3 0.088 0.033 
4 0.172 0.243 
5 0.896 0.271 
6 0.426 0.241 
7 1.04 0.501 
Mean 2.04 0.296 
SEM 1.18 0.09 
a b 
c 
d 
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Figure S1.  The selection and cellular activity of the IL-23 aptamer.  (a)  Functional 
activity following minimization and optimization of the IL-23 aptamer. (b) IL-23 aptamer 
inhibition of endogenous IL-23 in the PHA Blast phospho-STAT3 assay. (c)  Activity of the 
IL-23 aptamer against eIL-23 and rIL-12. (d) Percent inhibition by p19 neutralizing antibody 
and the IL-23 aptamer in the PHA Blast phospho-STAT3 assay from individual donors. 
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Supplementary Information.  S2 
In vitro selection of IL-23 modified RNA Aptamer 
The DNA library consisted of a 40-nucleotide random region (N40) flanked by two constant 
regions, 5’-GGAGGGAAAAGTTATCAGGC-N40-CGACGAGTAGGCTAGTCTGATGCC-
3’.  The template was amplified with a primer containing the T7 promoter sequence 5’-
GACTGTAATACGACTCACTATAGGAGGGAAAAGTTATCAGGC-3’ (underlined 
portion binds to DNA template).  The original library was created by transcribing the double 
stranded DNA templates as 2’-fluoro and 2’-methoxy modified RNA with a mutant T7 RNA 
polymerase (Y639) to incorporate the modified nucleotides (mA, mG, fC, and fU residues). 
The modified RNA library was purified by polyacrylamide gel electrophoresis (PAGE).  
The initial selection round contained 1014 molecules of library incubated at 37C for 1 hour 
with 1 M of recombinant Interleukin 23 (IL-23, from R&D Systems) in Dulbecco’s 
Phosphate Buffered Saline with calcium chloride and magnesium chloride (DPBS++).  
Aptamer:pool complex was partitioned using nitrocellulose filter plates pre-treated with 0.5M 
KOH.  Washes used DPBS++ and the selected pools were eluted from filters with urea 
elution buffer (7M Urea, 100 mM NaOAc, 3 mM EDTA pH 5.7).  Eluted modified RNA was 
reverse transcribed with Thermoscript Reverse Transcriptase (Life Technologies) with the 
reverse primer, 5’-GGCATCAGACTAGCCTACTCGTCG-3’ and amplified by polymerase 
chain reaction (PCR) with Taq polymerase and both forward and reverse DNA primers. PCR 
product was transcribed using the same T7 RNA polymerase above, gel purified, and put in 
to the subsequent round.  The DNA pools from rounds were cloned into pUC19 and 
sequenced on an ABI 3730 sequencer to identify N40 DNA sequence of the full length IL-23 
aptamer (parent; precursor to IL-23 aptamer).  
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Supplementary Information.  S3 
Dual Hybridization Assay 
The dual hybridization assay (DHA) has been previously used with plasma and vitreous 
humour samples (Drolet et al, 2000).  This assay is analogous to an ELISA where aptamer is 
allowed to hybridize to capture and detection DNA oligonucleotide probes.  The capture 
probe (ARC35141; Integrated DNA Technologies) binds to the 13 nucleotides at the 5'-
terminus of the aptamer and was covalently attached to magnetic beads via a 3'-terminal 
amino linker.  The detection probe (ARC35156; Integrated DNA Technologies) was 
complementary to the 15 nucleotides at the 3'-terminus of the aptamer and was biotinylated at 
the 5'-terminus.   
DHA assay plates were prepared by coating 96 well plates with 100 μL of capture probe (250 
nM in 1mM EDTA/DPBS) and incubated at 4°C overnight.  The capture probe solution was 
removed and the plate washed with 3 x 300 μL of wash buffer (Tris buffered saline with 
Tween; TBST) with a minimum of 1 minute soaking time for each of the 3 washes cycles and 
the plate was tapped out on absorbent paper after each wash.  Following removal of wash 
buffer, 200 μL of blocking solution (5 % w/v BSA in TBST) was added to each well and the 
assay plate was sealed and incubated at room temperature for 60 minutes on an orbital shaker.  
The blocking solution was removed and the plate washed as above.  A standard curve of 
aptamer was prepared by doubling dilutions to produce standards from 10 nM to 10 pM and 
DPBS as a blank sample (0 pM) was added in duplicate (60 μL per well) to a fresh 96 well 
plate (hybridisation plate).  The extracted epidermis and dermis samples were added to the 
hybridisation plate (60 μL). To each well, 60 µL of the detection probes (150 nM in DPBS) 
was added. The final concentration of detection probes was 75 nM and aptamer standard 
concentrations were from 0 pM, 5 nM to 5 pM.  The hybridization plate was sealed and 
placed in an oven at 65°C for 40 minutes to allow the aptamer to hybridise with the probes, 
and then allowed to cool to room temperature.  One hundred µL of the aptamer 
standard/sample:detection probe mixture was transferred from the hybridization plate to a 
DHA assay plate, sealed and incubated overnight at 4°C to allow hybridization of the aptamer 
and capture probes.  This assay solution was removed and the plate washed with TBST as 
above.  One hundred µL of the streptavidin-poly-HRP diluted 1:20,000 with DPBS was 
added to the DHA assay plate, which was then sealed and incubated at room temperature for 
1 hour while shaking.  The streptavidin-poly-HRP solution was removed and the plate again 
washed with TBST before 100 μL of the TMB substrate solution (at room temperature) was 
added to each well; the plates were incubated at room temperature for 5 minutes until 
sufficient colour developed.  Stop solution (100 μL) was added to each well and the plate was 
read at 450 nm within 30 minutes after stopping the reaction.  Data analysis used Prism 5 for 
each plate, the background A450 value (0 pM aptamer) was subtracted from all values within 
the sample set.  The recovered aptamer (mass per cm2) was converted to concentration 
(µmol/L) in each skin layer where the volume of epidermis (cm3) was assumed to be 0.015 
cm3 and the volume of dermis was assumed to be 0.035 cm3.  The dosing area was 1cm2.   
  
28 
 
Supplementary Information.  S4 
Th17 Stimulated Human Ex-Vivo Skin Model 
Cornification media:  Media consisted of 237 mL of Dulbecco's Modified Eagle Medium 
(DMEM) with 4.0 mM L-Glutamine and without CaCl, Glucose, Sodium Pyruvate, and 
NaHCO3 (Invitrogen, custom order), 237 mL Ham's F-12K (Kaighn's) Medium (Gibco®, 
21127-022), 1 mL 90mM Adenine, 1mL 0.94M CaCl, 1 mL 10nM Tri-iodothyronine, 1 mL 
Insulin-Transferrin-Selenium-Ethanolamine (ITS -X) (100X) (Gibco®  5100-056), 5 mL 
Antibiotic-Antimycotic (100X) (Gibco® 15240-062), 10 mL Foetal Bovine Serum (FBS) 
(HyCloneTM, SH30071.01HI), 5 mL GlutaMAX™ Supplement (Gibco®, 35050-061), 0.1 
mL 50mg/ml Gentamicin (Invitrogen, #15750060). 
Th17 Stimulation Cocktail:  The cytokine cocktail was optimized to stimulate skin resident 
immune cells to release TH17 associated cytokines, including IL-17f and IL-22, as previously 
described 16.  Briefly, skin was stimulated with a combination of 1 µg/ml purified NA/LE 
Mouse anti-human CD3 (BD Pharmingen, Cat# 555329) and 2 µg /ml anti-human CD28 
(R&DSystems, Cat# MAB342), 1 µg /ml anti-Human IFN-gamma Antibody (R&DSystems, 
Cat#MAB2851), 1 µg/ml anti-Human IL-4 Antibody (R&DSystems, Cat# MAB304), 10 
ng/ml Recombinant Human (rh) IL-1b/IL-1F2 (R&DSystems, Cat# 201-LB-025/CF), 10 
ng/ml rhIL-6 (R&DSystems, Cat# 206-IL-010/CF), 1 ng/ml Recombinant Human TGF-b1 
(R&DSystems, Cat# 240-B-010/CF), and rh IL-21 (Southern Biotech, Cat# 19000-00).  All 
components were incorporated in a single mixture with the cornification media. 
Tissue culture using Static Cells:  Freshly excised healthy human skin was dermatomed to 
750 µm and cleaned with antibiotic/antimycotic solution made up as 1% Gibco™ Antibiotic-
Antimycotic (100X), 0.1% Gentamicin in 1x Dulbecco's Phosphate Buffered Saline.  Twelve 
mm diameter biopsies were cut using disposable single-use biopsy punches (Acupunch, 
Acuderm, Inc) and washed in antibiotic/antimycotic solution for 5-10 minutes.  Skin biopsies 
were placed on autoclaved 7 mm (0.38 cm2) unjacketed static cells with 2 mL receptor 
volume (PermeGear, Inc; No. 6G-01-00-07-02) and a leak proof seal was maintained using 
metal clamps and donor chamber.  The receptor chamber was filled with cornification media.  
Static cells were then placed in a humidified incubator at 37°C and cultured as previously 
described (Smith et al, 2016).  First, test articles were dosed topically or systemically in the 
media and twenty-four hours later, the media was replaced and the Th17 stimulation cocktail 
was added to the receptor chamber of the Franz cells.  Twenty-four hours after stimulation, 
the tissue was harvested, minced to less than 1x1x1 mm pieces and stored in 10x volume of 
RNA later (Qiagen, Cat# 76104) with 300 µL of RNeasy Lysis Buffer (Qiagen, Cat#79216) 
supplemented with 1% 2-Beta-Mercapto-Ethanol for RNA isolation. 
Small Molecule Control:  A ROR gamma inverse agonist (MW=476 g/moles) was used as a 
positive control at 10 µM in cornification media based on its known positive activity in the 
Th17 stimulated human ex vivo skin model (Smith et al, 2016). 
RNA Isolation & Quantitation: Approximately 40 mg of minced tissue was added to 
homogenization tubes containing 2.8 and 1.4 mm ceramic beads.  The tissue was disrupted 
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using a high-throughput bead mill homogenizer (Precellys®24 Atkinson, NH) at 6300 rpm 
for 30 seconds and 10 cycles with a 2-minute ice break.  The homogenate was digested by 
adding 490 µL of water containing 10 µL Proteinase K (Thermo Scientific, Cat # E00491) at 
55°C for 15 minutes.  Digested tissue was spun down for 3 minutes at 10,000x g to pellet cell 
debris and the supernatant was used for RNA isolation using Qiagen’s Mini RNA Isolation 
kit (Cat # 74106) according to the manufacturer’s protocol.  Total RNA was quantified using 
a Nanodrop 2000 (Thermo Scientific, Wilmington, DE).  Isolated RNA (1.4µg) from skin 
tissue was used as a template in a 20 µL PCR volume using an Invitrogen SuperScript VILO 
cDNA Synthesis kit (# 11754-050) to create a cDNA template.  The cDNA was diluted 1:25 
for subsequent qPCR with the specific TaqMan probe for each gene to be quantified.  A Life 
Technologies AVii7 PCR machine was used for the qPCR 40 amplification cycles.  RNA 
levels of GAPDH, IL-17a, IL-17f and IL-22 relative expression were calculated using the 
ΔΔCT method. 
 
 
